AFT Completes Successful Development of Maxigesic Rapid

Market release 1 March 2019 AFT Pharmaceuticals Completes Successful Development of Maxigesic Rapid AFT Pharmaceuticals has successfully completed development of a faster release version of its dual action pain-killer, Maxigesic. Maxigesic comprises two active ingredients, paracetamol [acetaminophen] and ibuprofen in a synergistic ratio. Following an agreement which in-licensed specialist patented technology, a new formulation of Maxigesic has been developed which releases one of the key components, ibuprofen, much faster in comparison with a standard Maxigesic tablet. "We see this as an advantage as new technology allows the ibuprofen component to be dissolved into the stomach much faster" said Dr Hartley Atkinson, CEO of AFT Pharmaceuticals. Additional Intellectual Property has been generated around these findings and a further patent application has also been recently filed. "Following a recent FDA meeting, the first registration of Maxigesic Rapid is underway and expected within the next 12 months in the USA" noted Dr Atkinson. The US market is of particular interest as it is the largest pharmaceutical market in the world. The market defined by Euromonitor in 2018 for oral dose forms of analgesics for adults is close to US$4 billion. [End of Release] For more information: Dr Hartley Atkinson, CEO, AFT Pharmaceuticals Ltd Phone: +64 9 488 0232 Email: hartley@aftpharm.com About MAXIGESIC(R) MAXIGESIC(R) is a unique, patented combination of paracetamol and ibuprofen that provides fast, effective double action pain relief from a wide range of pain. https://www.aftpharm.com About AFT AFT is a growing multinational pharmaceutical business with a broad range of products, both developed itself and in-licensed from third parties. AFT's products cover all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. Historically, AFT's home markets have been Australia, New Zealand and South-East Asia. However the company is out-licensing its own products to licensees and distributors to sell in an increasing number of countries around the world. The company's intensive Research and Development programme forms the basis of its international sales strategy. For more information about the company, visit aftpharm.com End CA:00331327 For:AFT Type:GENERAL Time:2019-03-01 08:53:31